Publications
156
Citations
1,603
Est. group size
~33
Recurring co-author estimate
Active years
14
Publishing since 2013
Evandro D. Bezerra's research focuses on CAR T-cell therapy, a treatment that reprograms a patient's own immune cells to attack cancer, particularly for blood cancers such as leukemia and lymphoma. His work includes analyzing real-world patient outcomes from large treatment registries, identifying biomarkers that predict treatment response or side effects, and exploring ways to improve CAR T-cell effectiveness, such as combining it with drugs that inhibit the AXL protein. This research is aimed at understanding how to make CAR T-cell therapies safer and more effective for a broader range of blood cancer patients.
Publication output grew substantially from 2017 through 2023, peaking with a large increase in recent years, and has remained high with slight fluctuation through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Blood Advances · 2025
- Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis
Transplantation and Cellular Therapy · 2025
- Autologous Transplant or <scp>CAR</scp>‐T as Consolidation Options in <scp>MYC</scp> Rearranged Large B‐Cell Lymphoma Patients in Remission After Salvage Treatments
American Journal of Hematology · 2025
- NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
Transplantation and Cellular Therapy · 2025
- Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025
- Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025
- Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025
- Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025
- Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
Frontiers in Pediatrics · 2024
- Outcomes of <scp>CD19 CAR</scp> T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma
American Journal of Hematology · 2024
- NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
Blood · 2024
- Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
Blood · 2024
- Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024
- Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024
- Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024
- Blood×38
- Transplantation and Cellular Therapy×21
- Biology of Blood and Marrow Transplantation×5
- Blood Advances×5
- Leukemia×4
- Utkarsh Acharya
Medicine · The Ohio State University
- Daniel Li
Medicine · The Ohio State University
- Jay K. Mandula
Medicine · The Ohio State University
- Audrey M. Sigmund
Medicine · The Ohio State University
- Nathan Denlinger
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile